Cargando…

1075. In vitro Activity of Gepotidacin against Escherichia coli Causing Urinary Tract Infections in the United States, Including Molecularly Characterized Fluoroquinolone Resistant Subsets

BACKGROUND: Gepotidacin (GEP) is a novel bacterial type II topoisomerase inhibitor in Phase 3 clinical trials for the treatment of gonorrhea and uncomplicated urinary tract infections (UTI). This study characterized fluoroquinolone (FQ)-not susceptible (not S) E. coli causing UTI in U.S. patients an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mendes, Rodrigo E, Doyle, Timothy B, Arends, S J Ryan, Butler, Deborah, Scangarella-Oman, Nicole, Streit, Jennifer M, Castanheira, Mariana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643800/ http://dx.doi.org/10.1093/ofid/ofab466.1269

Ejemplares similares

Antimicrobial Activity of Gepotidacin Tested against Escherichia coli and Staphylococcus saprophyticus Isolates Causing Urinary Tract Infections in Medical Centers Worldwide (2019 to 2020)
por: Arends, S. J. Ryan, et al.
Publicado: (2023)

1262. Antimicrobial Activity of Gepotidacin against Clinical Isolates of Escherichia coli and Staphylococcus saprophyticus Collected Worldwide in 2019
por: Arends, S J Ryan, et al.
Publicado: (2020)

1254. Molecular Epidemiology of Escherichia coli Causing Urinary Tract Infections in United States and in vitro Activity of Tebipenem, Including Against Strain Lineage and Resistant subsets (2018-2020)
por: Mendes, Rodrigo E, et al.
Publicado: (2021)

1062. Analysis of Resistance to Oral Standard of Care Antibiotics for Urinary Tract Infections Caused By Escherichia coli and Staphylococcus saprophyticus Collected Worldwide between 2019-2020
por: Arends, S J Ryan, et al.
Publicado: (2021)

Dose Selection for Phase III Clinical Evaluation of Gepotidacin (GSK2140944) in the Treatment of Uncomplicated Urinary Tract Infections
por: Scangarella-Oman, Nicole E., et al.
Publicado: (2022)

701. Comparison of MIC Results for Gepotidacin by Agar Dilution and Broth Microdilution Methods
por: Arends, S J Ryan, et al.
Publicado: (2019)

1482. Microbiological Analysis from a Phase II Study Evaluating Gepotidacin (GSK2140944) in the Treatment of Uncomplicated Urinary Tract Infections
por: Scangarella-Oman, Nicole, et al.
Publicado: (2019)

714. Analysis of the Effect of Urine on the In Vitro Activity of Gepotidacin and Levofloxacin Against Escherichia coli, Staphylococcus epidermidis, and Staphylococcus saprophyticus
por: Koeth, Laura M, et al.
Publicado: (2019)

Design of Two Phase III, Randomized, Multicenter Studies Comparing Gepotidacin with Nitrofurantoin for the Treatment of Uncomplicated Urinary Tract Infection in Female Participants
por: Perry, Caroline, et al.
Publicado: (2022)

1479. Clinical Efficacy and Safety Analysis Evaluating Oral Gepotidacin (GSK2140944) from a Phase IIa Study in the Treatment of Uncomplicated Urinary Tract Infections
por: Overcash, J Scott, et al.
Publicado: (2019)

2159. Analysis of Resistance to Oral Standard-of-Care Antibiotics for Urinary Tract Infections Caused By Escherichia coli and Staphylococcus saprophyticus Collected in the United States in 2022
por: Arends, S J Ryan, et al.
Publicado: (2023)

724. The In Vitro Activity of Gepotidacin and Comparator Agents Against Anaerobic Bacterial Isolates
por: Hackel, Meredith, et al.
Publicado: (2019)

1281. Longitudinal and Spatial Variation in the Human Microbiome in a Phase 2a Clinical Study of Gepotidacin in Adult Females with Uncomplicated Urinary Tract Infection
por: Nuzzo, Andrea, et al.
Publicado: (2020)

1480. Plasma and Urine Pharmacokinetic Analysis of Gepotidacin (GSK2140944) Following BID Oral Dosing in a Phase IIa Study for Treatment of Uncomplicated Urinary Tract Infections
por: Zimmerman, Eric I, et al.
Publicado: (2019)

Contemporary Evaluation of Tebipenem In Vitro Activity against Enterobacterales Clinical Isolates Causing Urinary Tract Infections in US Medical Centers (2019–2020)
por: Mendes, Rodrigo E., et al.
Publicado: (2023)

1057. Tebipenem In vitro Activity Against a Collection of Pathogens Responsible for Urinary Tract Infections in the US
por: Mendes, Rodrigo E, et al.
Publicado: (2021)

Microbiome recovery in adult females with uncomplicated urinary tract infections in a randomised phase 2A trial of the novel antibiotic gepotidacin (GSK140944)
por: Nuzzo, Andrea, et al.
Publicado: (2021)

In Vitro Activity of Gepotidacin against Gram-Negative and Gram-Positive Anaerobes
por: Hackel, Meredith A., et al.
Publicado: (2022)

Correction to: Microbiome recovery in adult females with uncomplicated urinary tract infections in a randomised phase 2A trial of the novel antibiotic gepotidacin (GSK2140944)
por: Nuzzo, Andrea, et al.
Publicado: (2021)

Phase 2a Pharmacokinetic, Safety, and Exploratory Efficacy Evaluation of Oral Gepotidacin (GSK2140944) in Female Participants with Uncomplicated Urinary Tract Infection (Acute Uncomplicated Cystitis)
por: Overcash, J. Scott, et al.
Publicado: (2020)

Gepotidacin Pharmacokinetics-Pharmacodynamics against Escherichia coli in the One-Compartment and Hollow-Fiber In Vitro Infection Model Systems
por: VanScoy, Brian D., et al.
Publicado: (2021)

In vitro activity of the first-in-class triazaacenaphthylene gepotidacin alone and in combination with doxycycline against drug-resistant and -susceptible Mycoplasma genitalium
por: Jensen, Jørgen Skov, et al.
Publicado: (2020)

2832. Gepotidacin Efficacy in E. coli Drug-Resistant Phenotypes: A Pooled Analysis of the EAGLE-2 and EAGLE-3 Randomized Controlled Trials in Uncomplicated Urinary Tract Infection
por: Hooton, Thomas M, et al.
Publicado: (2023)

P31 Efficacy and safety of oral gepotidacin in the treatment of uncomplicated urinary tract infection: results of two randomized, multicentre Phase 3 trials (EAGLE-2 and EAGLE-3)
por: Wagenlehner, Florian, et al.
Publicado: (2023)

1059. In vitro Activity of Exebacase (CF-301) against Staphylococcus aureus Causing Bacteremia in the United States, Including Multidrug-resistant Subsets
por: Mendes, Rodrigo E, et al.
Publicado: (2021)

1249. Genetic Evidence That Gepotidacin Shows Well-balanced Dual Targeting against DNA Gyrase And Topoisomerase IV in Neisseria gonorrhoeae
por: Chan, Pan, et al.
Publicado: (2020)

Dose selection for a phase III study evaluating gepotidacin (GSK2140944) in the treatment of uncomplicated urogenital gonorrhoea
por: Scangarella-Oman, Nicole E, et al.
Publicado: (2023)

2837. Impact of Regulatory Guidelines on Therapeutic, Clinical, and Microbiological Success Rates in Uncomplicated Urinary Tract Infection: Results from a Two Phase 3 Randomized Controlled Trials of Oral Gepotidacin (EAGLE-2 and EAGLE-3)
por: Wagenlehner, Florian, et al.
Publicado: (2023)

Efficacy, Safety, and Tolerability of Gepotidacin (GSK2140944) in the Treatment of Patients with Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
por: O'Riordan, William, et al.
Publicado: (2017)

1047. Global Surveillance: Susceptibility of Ceftolozane–Tazobactam Against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa Isolates Collected From Bloodstream Infections in the United States From 2015 to 2017
por: Arends, S J Ryan, et al.
Publicado: (2018)

High fluoroquinolone MIC is associated with fluoroquinolone treatment failure in urinary tract infections caused by fluoroquinolone susceptible Escherichia coli
por: Rattanaumpawan, Pinyo, et al.
Publicado: (2017)

Efficacy and Safety of Gepotidacin as Treatment of Uncomplicated Urogenital Gonorrhea (EAGLE-1): Design of a Randomized, Comparator-Controlled, Phase 3 Study
por: Perry, Caroline R., et al.
Publicado: (2023)

155. In Vitro Evaluation of Delafloxacin Activity Against Contemporary US Isolates from Community-Acquired Pneumonia and Community-Acquired Lower Respiratory Tract Infections: Results from the SENTRY Antimicrobial Surveillance Program (2014-2020)
por: Shortridge, Dee, et al.
Publicado: (2021)

Activity of Oritavancin against Gram-Positive Pathogens Causing Bloodstream Infections in the United States over 10 Years: Focus on Drug-Resistant Enterococcal Subsets (2010–2019)
por: Carvalhaes, Cecilia G., et al.
Publicado: (2022)

1278. Impact of Different Breakpoint Criteria on the Susceptibility Rates of Enterobacterales resistant Subsets to the Aminoglycosides
por: Sader, Helio S, et al.
Publicado: (2020)

Relationship between Gepotidacin Exposure and Prevention of On-Therapy Resistance Amplification in a Neisseria gonorrhoeae Hollow-Fiber In Vitro Infection Model
por: VanScoy, Brian D., et al.
Publicado: (2020)

Novel Bacterial Topoisomerase Inhibitor Gepotidacin Demonstrates Absence of Fluoroquinolone-Like Arthropathy in Juvenile Rats
por: Fishman, Cindy, et al.
Publicado: (2022)

Minocycline Activity against Unusual Clinically Significant Gram-Negative Pathogens
por: Shortridge, Dee, et al.
Publicado: (2021)

Gepotidacin for the Treatment of Uncomplicated Urogenital Gonorrhea: A Phase 2, Randomized, Dose-Ranging, Single-Oral Dose Evaluation
por: Taylor, Stephanie N, et al.
Publicado: (2018)

1305. Antimicrobial Activity of Ceftaroline and Comparator Agents against Ceftriaxone-Non-Susceptible Streptococcus pneumoniae from the United States (2008-2020)
por: Sader, Helio S, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ukhpssmvqeh5m8oa7r3do8st3h